CN108159011A - 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 - Google Patents
一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 Download PDFInfo
- Publication number
- CN108159011A CN108159011A CN201810234449.2A CN201810234449A CN108159011A CN 108159011 A CN108159011 A CN 108159011A CN 201810234449 A CN201810234449 A CN 201810234449A CN 108159011 A CN108159011 A CN 108159011A
- Authority
- CN
- China
- Prior art keywords
- weight
- controlled release
- pharmaceutical composition
- pregabalin
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 title claims abstract description 47
- 229960001233 pregabalin Drugs 0.000 title claims abstract description 46
- 238000013270 controlled release Methods 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 230000002051 biphasic effect Effects 0.000 title claims abstract description 10
- 210000002784 stomach Anatomy 0.000 title abstract description 32
- 238000013268 sustained release Methods 0.000 title abstract description 24
- 230000014759 maintenance of location Effects 0.000 title abstract description 23
- 239000012730 sustained-release form Substances 0.000 title abstract description 23
- 239000000463 material Substances 0.000 claims abstract description 11
- 230000000694 effects Effects 0.000 claims abstract description 8
- 239000000945 filler Substances 0.000 claims abstract description 6
- 239000000314 lubricant Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 7
- 239000004925 Acrylic resin Substances 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- -1 polypropylene Polymers 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 229920002301 cellulose acetate Polymers 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims 2
- 229920002678 cellulose Polymers 0.000 claims 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims 1
- 229920001353 Dextrin Polymers 0.000 claims 1
- 239000004375 Dextrin Substances 0.000 claims 1
- 239000004743 Polypropylene Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 235000019425 dextrin Nutrition 0.000 claims 1
- 239000005038 ethylene vinyl acetate Substances 0.000 claims 1
- 238000005461 lubrication Methods 0.000 claims 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 claims 1
- 229920001155 polypropylene Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000000661 sodium alginate Substances 0.000 claims 1
- 235000010413 sodium alginate Nutrition 0.000 claims 1
- 229940005550 sodium alginate Drugs 0.000 claims 1
- 238000002156 mixing Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000008186 active pharmaceutical agent Substances 0.000 abstract description 2
- 238000003825 pressing Methods 0.000 abstract description 2
- 239000003826 tablet Substances 0.000 description 16
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 238000000034 method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 3
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 3
- 229960003529 diazepam Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 description 1
- 229920000178 Acrylic resin Polymers 0.000 description 1
- 101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000005915 GABA Receptors Human genes 0.000 description 1
- 108010005551 GABA Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100024304 Protachykinin-1 Human genes 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 101800003906 Substance P Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明提供了一种双相控释的普瑞巴林胃滞留缓释片及其制备方法,该发明包含5重量%至60重量%的活性药物成分,5重量%至60重量%的不溶性骨架控释相,1重量%至50重量%的凝胶骨架控释相,0重量%至30重量%的填充剂,0.5重量%至5重量%的润滑剂,通过双相控释,可以最大程度的减小个体差异带来的释放差异,实现胃部滞留,起到良好的缓释效果,所选用的辅料流动性好,抗粘性强,可在混合后直接压制得到普瑞巴林胃滞留缓释片,缩短了生产时间。
Description
技术领域
本发明属于药物制剂领域,具体涉及一种双相控释的普瑞巴林胃滞留缓释片,粉末直压制备工艺,用于治疗外周神经痛的制剂,适合每日口服一次。
技术背景
普瑞巴林是一种γ-氨基丁酸的类似物,但是在GABA受体上并无结合活性位点,因此普瑞巴林在体内并不代谢转变成GABA或GABA拮抗剂,因而也不会影响GABA的摄取和代谢。普瑞巴林是脑和脊髓神经元末梢突触前膜上的电压门控钙离子通道上α2δ亚基的特定配体,当普瑞巴林作用于α2δ亚基蛋白的特定结合位点,钙离子通道打开,钙离子内流进入突触,使一些兴奋性神经递质如谷氨酸、去甲肾上腺素、物质P等释放减少,该作用机制使得普瑞巴林对慢性疼痛、癫痫、抗焦虑等具有疗效。
普瑞巴林口服吸收良好,生物利用度大于90%,且不受剂量影响,禁食给药后约1h达到最大峰浓度,消除半衰期约为6h。普瑞巴林对于细胞色素P450酶无影响,不存在显著的药物-药物相互作用。
目前,国内销售的普瑞巴林制剂有辉瑞公司的乐瑞卡速释胶囊(25、50、75、100、125、150、200、225、300mg规格),以及重庆赛维药业有限公司的速释胶囊(25、75、100mg规格),治疗时均需每日给药2~3次。普瑞巴林具有较高的溶解度与溶出速率,多次给药会引起血药浓度波动,且普瑞巴林的吸收主要在小肠和升结肠,在结肠肝曲以外的部位吸收较少。常规的速释剂型与缓释剂型一般情况下会在6h内通过结肠肝曲,说明普瑞巴林常规剂型释放6h以外的药物会被浪费。因此,将普瑞巴林制备成一日给药一次的直压型缓释片,可增加普瑞巴林在胃部和小肠上端的吸收,增加生物利用度,提高患者顺应性,平稳血药浓度,且工艺简便易行,成本低廉,适于工业化生产。而通过双相骨架控释,可以最大程度的减小个体差异带来的释放差异,实现缓释作用,
中国专利申请号CN201210293112为含普瑞巴林的每日口服一次的控释制剂,该专利使用产气剂碳酸钙、碳酸镁、碳酸氢钠,在胃内产生CO2,达到胃漂浮并实现控释的目的。中国专利申请号CN201510252515为含普瑞巴林的每日一次的胃漂浮缓释片,该专利使用普瑞巴林5~40%,10~40%骨架材料,1~20%膨胀剂,10~40%助漂剂,5~40%稀释剂,其特征在于胃漂浮缓释片接触胃液后,片剂表面形成水凝胶层,体积膨胀,片剂的密度小于胃液使片剂漂浮于胃液表面,达到长时间滞留于胃内的效果。根据文献报道,胃漂浮系统需要大量胃液,对胃内容物密度具有要求,且人体胃酸的酸度与进食、生理节律、年龄性别等均有关,患者的个体差异会导致胃漂浮制剂在胃液较少或胃内pH较高的患者体内无法漂浮,失去缓控释效果。
中国专利授权号CN101330907B为辉瑞公司研制的含普瑞巴林、基质形成剂和溶胀剂并适于每日口服一次的固体药物组合物,该专利公开了一种接触水时可膨胀至9mm或更大尺寸的药物组合物,通过尺寸排斥法实现胃滞留,该专利对应的普瑞巴林缓控释制剂已于2017年10月在美国批准上市。对比不溶性丙烯酸树脂和羟丙甲基纤维素组成的双相控释系统与该专利中的基质形成剂聚醋酸乙烯酯和乙烯吡咯烷酮物理混合物,双相控释系统可以提供更好的纵向膨胀性,并维持适宜的片型与刚性。
中国专利申请号CN201310024603提供了一种普瑞巴林渗透胃滞留片,该专利通过膨胀和渗透泵原理,使渗透胃滞留片在胃中长时间滞留并实现零级释放。但该专利为打孔渗透泵制剂,对激光或者其他的机械打孔设备具有较高的要求,单面或双面释药孔释放药物可能引起局部药物浓度过高产生的副作用,而释药孔堵塞易造成药物无法释放。
中国专利申请号CN201510707915提供了一种普瑞巴林缓释片药物组合物,包含普瑞巴林10~80%,缓释材料20~80%,填充剂70~140%,润滑剂1~6%,薄膜包衣粉1~5%,总混后直接压片,可持续释药24h。该普瑞巴林缓释片为非胃滞留缓控释系统。
发明内容
本发明的目的是提供一种双相控释的普瑞巴林胃滞留缓释片及其制备方法,该发明包含5重量%至60重量%的活性药物成分,5重量%至60重量%的不溶性骨架控释相,1重量%至50重量%的凝胶骨架控释相,0重量%至30重量%的填充剂,0.5重量%至5重量%的润滑剂。通过双相控释,可以最大程度的减小个体差异带来的释放差异,实现缓释作用,且所选用的辅料流动性好,抗粘性强,可在混合后直接压制得到普瑞巴林胃滞留缓释片,缩短了生产时间。
本发明所述的不溶性骨架控释相选自乙基纤维素、聚丙烯酸树脂、交联聚维酮、乙烯-醋酸乙烯共聚物、醋酸纤维素中的一种或它们的混合物。
本发明所述的凝胶骨架控释相选自羟丙甲纤维素、羟丙纤维素、卡波姆、海藻酸钠、黄原胶、聚氧乙烯中的一种或它们的混合物。
本发明所述的填充剂选自淀粉、乳糖、蔗糖、甘露醇、微晶纤维素、预胶化淀粉、糊精、无机盐类中的一种或它们的混合物。
本发明所述的不溶性骨架优选聚丙烯酸树脂,如聚丙烯酸树脂II、尤特奇RS、尤特奇RL中的一种或它们的混合物。
本发明所述的凝胶骨架材料优选羟丙甲基纤维素,如羟丙甲纤维素K100LV、K4M、K15M、K100M中的一种或它们的混合物。
本发明所述的普瑞巴林胃滞留缓释片,其制备过程为:(a)将普瑞巴林或其药学上可接受的盐与不溶性骨架控释相、凝胶骨架控释相混合;(b)将(a)中所得混合物与润滑剂混合,随后压制得到片剂。
本发明所述的普瑞巴林胃滞留缓释片接触介质后可膨胀至9毫米或更大尺寸,在胃中可滞留12小时或更长时间。
本发明所述的普瑞巴林胃滞留缓释片,口服后达到最高血药浓度的时间(Tmax)为4至10小时。
本发明的一个目的是提供了一种实质上改进治疗外周神经痛的方法。
本发明的另一个目的是减少患者每日服药次数,提高患者治疗的顺应性,避免或减小血药浓度大幅度波动,降低毒副作用。
上述目的及其他目的可凭借本发明实现,本发明涉及固体缓释口服剂型,该剂型包括5重量%至60重量%的普瑞巴林,其中剂型的体外释放率(采用中国药典2015年版四部通则0931溶出度与释放度测定法第二法释放装置,使用沉降篮,于900mL 0.06N盐酸溶液介质中37℃,50rpm条件下测定)。
附图说明:
图1为实施例1普瑞巴林胃滞留缓释片释放曲线
图2为实施例2普瑞巴林胃滞留缓释片释放曲线
图3为实施例3普瑞巴林胃滞留缓释片释放曲线
图4为实施例4普瑞巴林胃滞留缓释片释放曲线
图5为实施例5普瑞巴林胃滞留缓释片释放曲线
图6为实施例6普瑞巴林胃滞留缓释片释放曲线
图7为实施例6普瑞巴林胃滞留缓释片膨胀曲线
图8为实施例7普瑞巴林胃滞留缓释片与普瑞巴林速释胶囊在比格犬体内血药浓度-时间曲线
具体实施方式
实施例1
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
物料流动性 | 硬度(kg/cm2) | 脆碎度(%) | 粘冲情况 | 片剂外观 |
好 | 18~20 | 0.074 | 不粘冲 | 类白色,光滑,平整 |
实施例2
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
物料流动性 | 硬度(kg/cm2) | 脆碎度(%) | 粘冲情况 | 片剂外观 |
好 | 18~20 | 0.054 | 不粘冲 | 类白色,光滑,平整 |
实施例3
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
物料流动性 | 硬度(kg/cm2) | 脆碎度(%) | 粘冲情况 | 片剂外观 |
好 | 18~20 | 0.034 | 不粘冲 | 类白色,光滑,平整 |
实施例4
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
物料流动性 | 硬度(kg/cm2) | 脆碎度(%) | 粘冲情况 | 片剂外观 |
好 | 18~20 | 0.039 | 不粘冲 | 类白色,光滑,平整 |
实施例5
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
物料流动性 | 硬度(kg/cm2) | 脆碎度(%) | 粘冲情况 | 片剂外观 |
好 | 18~20 | 0.081 | 不粘冲 | 类白色,光滑,平整 |
实施例6
制备工艺:将除硬脂酸镁以外的原辅料在三维立体混合机中混合30min后,加入硬脂酸镁继续混合5min,使用旋转压片机,20×12mm水滴形冲压制成片剂。
各指标检测结果:
将实施例6制得的普瑞巴林胃滞留缓释片按照《中国药典》2015年版四部通则0931溶出度与释放度测定法第二法释放装置,使用沉降篮,在50rpm下于900mL 0.06N盐酸溶液介质中37℃下进行试验,将胃滞留缓释片投入介质中开始计时,分别在1h、2h、4h、6h、8h、12h、24h定时将沉降篮及药片取出,采用直尺测量长、宽、厚。结果见下表所示。
时间(h) | 长(mm) | 宽(mm) | 厚(mm) |
0 | 20.00 | 12.00 | 8.00 |
1 | 23.00 | 14.50 | 11.17 |
2 | 23.67 | 14.67 | 11.33 |
4 | 23.67 | 14.83 | 12.50 |
6 | 24.67 | 15.17 | 13.33 |
8 | 24.67 | 15.33 | 13.67 |
12 | 25.50 | 15.33 | 13.83 |
24 | 26.17 | 16.50 | 15.50 |
实施例7药动学评价
采用双周期双交叉给药设计。以市售制剂(乐瑞卡胶囊,辉瑞公司,150mg)为参比制剂,以实施例6中的普瑞巴林胃滞留缓释片为受试制剂。取beagle犬4只,犬编号分别为1、2、3、4,体重在8.9~9.7kg之间,均分为2组,将beagle犬于试验前一晚禁食12h,次日早晨于早餐30min后给药。第一周期,1、2号犬给予参比制剂,3、4号犬给予受试制剂,剂量均为一个单位。给予参比制剂的beagle犬,于给药后0,0.25,0.5,0.75,1,2,3,4,6,8,12,24,36,48h在前肢静脉丛采血3mL,置于肝素抗凝管内,4000rpm离心10min,存放在-20℃条件下备用;给予受试制剂的beagle犬,于给药后0,0.5,1,2,3,4,5,6,8,10,12,24,36,48h在前肢静脉丛采血3mL,同法处理血浆。经过1周洗净期后,进行交叉给药,3、4号犬给予参比制剂,1、2号犬给予受试制剂。
血浆样品处理:取beagle犬血浆400μL,衍生化后,取20μL进行HPLC分析。
受试制剂和参比制剂中普瑞巴林在beagle犬体内饱腹给药的血药浓度-时间曲线见图8。
Beagle犬体内试验证明,本发明的普瑞巴林胃滞留缓释片在饱腹条件下与乐瑞卡速释胶囊相比,Cmax显著降低,Tmax显著延长,相对生物利用度为107.06±9.79%。
Claims (9)
1.一种双相控释的普瑞巴林药物组合物,所述组合物包含5重量%至60重量%的活性药物成分,5重量%至60重量%的不溶性骨架控释相,1重量%至50重量%的凝胶骨架控释相,0重量%至30重量%的填充剂,0.5重量%至5重量%的润滑剂。
2.如权利要求1所述药物组合物,其中所述不溶性骨架控释相选自乙基纤维素、聚丙烯酸树脂、交联聚维酮、乙烯-醋酸乙烯共聚物、醋酸纤维素中的一种或它们的混合物。
3.如权利要求1所述的药物组合物,其中所述凝胶骨架控释相选自羟丙甲纤维素、羟丙纤维素、卡波姆、海藻酸钠、黄原胶、聚氧乙烯中的一种或它们的混合物。
4.如权利要求1所述的药物组合物,其中所述填充剂选自淀粉、乳糖、蔗糖、甘露醇、微晶纤维素、预胶化淀粉、糊精、无机盐类中的一种或它们的混合物。
5.如权利要求1所述药物组合物,其特征在于所述不溶性骨架优选聚丙烯酸树脂,如聚丙烯酸树脂II、尤特奇RS、尤特奇RL中的一种或它们的混合物。
6.如权利要求1所述药物组合物,其特征在于所述凝胶骨架材料优选羟丙甲基纤维素,如羟丙甲纤维素K100LV、K4M、K15M、K100M中的一种或它们的混合物。
7.如权利要求1所述药物组合物,所述药物组合物制备过程为:(a)将普瑞巴林或其药学上可接受的盐与不溶性骨架控释相、凝胶骨架控释相混合;(b)将(a)中所得混合物与润滑剂混合,随后压制得到片剂。
8.如权利要求1所述的药物组合物,其中所述药物组合物接触水后可膨胀至9毫米或更大尺寸,在胃中滞留12小时或更长时间。
9.如权利要求1所述药物组合物,其中口服后达到最高血药浓度的时间(Tmax)为4至10小时。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810234449.2A CN108159011A (zh) | 2018-03-16 | 2018-03-16 | 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810234449.2A CN108159011A (zh) | 2018-03-16 | 2018-03-16 | 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108159011A true CN108159011A (zh) | 2018-06-15 |
Family
ID=62512063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810234449.2A Pending CN108159011A (zh) | 2018-03-16 | 2018-03-16 | 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108159011A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109044981A (zh) * | 2018-08-07 | 2018-12-21 | 广州帝奇医药技术有限公司 | 一种普瑞巴林胃漂浮型缓释片及其制备方法 |
CN113116846A (zh) * | 2019-12-31 | 2021-07-16 | 广州玻思韬控释药业有限公司 | 胃滞留片 |
WO2022012172A1 (zh) * | 2020-07-17 | 2022-01-20 | 广州帝奇医药技术有限公司 | 一种难溶性药物口服缓释组合物及其制备方法 |
CN114028355A (zh) * | 2021-12-09 | 2022-02-11 | 南京海京康医药科技有限公司 | 一种普瑞巴林缓释片及其制备方法 |
WO2023279381A1 (zh) * | 2021-07-09 | 2023-01-12 | 上海博志研新药物研究有限公司 | 普瑞巴林的药物组合物及其制备方法和用途 |
CN115624532A (zh) * | 2022-11-02 | 2023-01-20 | 华润双鹤利民药业(济南)有限公司 | 一种普瑞巴林胃漂浮制剂及其制备方法 |
CN116059175A (zh) * | 2023-01-06 | 2023-05-05 | 重庆赛维药业有限公司 | 一种普瑞巴林胃漂浮缓释片及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013162114A1 (ko) * | 2012-04-27 | 2013-10-31 | 씨제이제일제당 주식회사 | 위체류 약물전달 시스템을 이용한 서방성 제제 |
US20140378545A1 (en) * | 2012-01-30 | 2014-12-25 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
WO2015114656A2 (en) * | 2014-01-22 | 2015-08-06 | Intas Pharmaceuticals Limited | Mucoadhesive tablet of pregabalin |
CN104906064A (zh) * | 2015-05-15 | 2015-09-16 | 中国药科大学 | 一种普瑞巴林胃漂浮缓释片剂及其制备方法 |
US20170172929A1 (en) * | 2014-04-07 | 2017-06-22 | Yungjin Pharm. Co., Ltd. | Pharmaceutical composition containing pregabalin with improved stability and method for preparing same |
-
2018
- 2018-03-16 CN CN201810234449.2A patent/CN108159011A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140378545A1 (en) * | 2012-01-30 | 2014-12-25 | Ranbaxy Laboratories Limited | Pregabalin gr tablets |
WO2013162114A1 (ko) * | 2012-04-27 | 2013-10-31 | 씨제이제일제당 주식회사 | 위체류 약물전달 시스템을 이용한 서방성 제제 |
WO2015114656A2 (en) * | 2014-01-22 | 2015-08-06 | Intas Pharmaceuticals Limited | Mucoadhesive tablet of pregabalin |
US20170172929A1 (en) * | 2014-04-07 | 2017-06-22 | Yungjin Pharm. Co., Ltd. | Pharmaceutical composition containing pregabalin with improved stability and method for preparing same |
CN104906064A (zh) * | 2015-05-15 | 2015-09-16 | 中国药科大学 | 一种普瑞巴林胃漂浮缓释片剂及其制备方法 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109044981A (zh) * | 2018-08-07 | 2018-12-21 | 广州帝奇医药技术有限公司 | 一种普瑞巴林胃漂浮型缓释片及其制备方法 |
CN109044981B (zh) * | 2018-08-07 | 2021-02-19 | 广州帝奇医药技术有限公司 | 一种普瑞巴林胃漂浮型缓释片及其制备方法 |
CN113116846A (zh) * | 2019-12-31 | 2021-07-16 | 广州玻思韬控释药业有限公司 | 胃滞留片 |
CN113116846B (zh) * | 2019-12-31 | 2024-03-19 | 广州玻思韬控释药业有限公司 | 胃滞留片 |
WO2022012172A1 (zh) * | 2020-07-17 | 2022-01-20 | 广州帝奇医药技术有限公司 | 一种难溶性药物口服缓释组合物及其制备方法 |
WO2023279381A1 (zh) * | 2021-07-09 | 2023-01-12 | 上海博志研新药物研究有限公司 | 普瑞巴林的药物组合物及其制备方法和用途 |
CN114028355A (zh) * | 2021-12-09 | 2022-02-11 | 南京海京康医药科技有限公司 | 一种普瑞巴林缓释片及其制备方法 |
CN115624532A (zh) * | 2022-11-02 | 2023-01-20 | 华润双鹤利民药业(济南)有限公司 | 一种普瑞巴林胃漂浮制剂及其制备方法 |
CN116059175A (zh) * | 2023-01-06 | 2023-05-05 | 重庆赛维药业有限公司 | 一种普瑞巴林胃漂浮缓释片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108159011A (zh) | 一种双相控释的普瑞巴林胃滞留缓释片及其制备方法 | |
CN104906064B (zh) | 一种普瑞巴林胃漂浮缓释片剂及其制备方法 | |
He et al. | Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: Preparation and in vitro/in vivo evaluation | |
CN1891229B (zh) | 预防或治疗代谢综合征的药物制剂 | |
CN101484153A (zh) | 一种胃滞留加巴喷丁剂型及其使用方法 | |
AU2010289022B2 (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
MX2012011022A (es) | Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas. | |
CN104840443B (zh) | 含活性成分普瑞巴林的药物组合物 | |
CN100358518C (zh) | 含特比萘芬的药物组合物及其应用 | |
JP7195345B2 (ja) | 薬物の時間放出のためのプログラム可能な医薬組成物 | |
CN113476421B (zh) | 一种非布司他的控释组合物及其制备方法 | |
JP2018520112A (ja) | 制御持続放出プレガバリン | |
ES2408343A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
CN105979936A (zh) | 一种普瑞巴林缓释制剂 | |
US10413514B2 (en) | Controlled-release solid preparation with partial coating | |
CN108348472A (zh) | 优化的含有高剂量美沙拉嗪的片剂 | |
KR20160060768A (ko) | 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손 | |
CN107961225A (zh) | 一种普瑞巴林微孔渗透泵片及其制备方法 | |
CN102058517A (zh) | 一种帕潘立酮缓释剂及其制备方法 | |
CN109432034A (zh) | 一种缬沙坦氨氯地平三层片剂及其制备方法 | |
CN104739797A (zh) | 一种释放速率递增的渗透泵片及其制备方法 | |
CN101524355A (zh) | 抗结核药物的复方制剂及其制备方法 | |
CN113143879A (zh) | 一种盐酸达泊西汀缓释片的制备方法 | |
CN102283816A (zh) | 西洛多辛缓释片剂及其制备方法 | |
CN101897678B (zh) | 头孢克洛缓释组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180615 |